Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 373

1.

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2007 Aug 15;13(16):4874-81.

2.

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2006 Apr 15;12(8):2622-7.

3.

Resistance to c-KIT kinase inhibitors conferred by V654A mutation.

Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK.

Mol Cancer Ther. 2007 Mar;6(3):1159-66.

4.

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.

Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, McKinley A, Patterson J, Taguchi T, Liang CW, Fletcher JA.

Mol Cancer Ther. 2012 Aug;11(8):1770-80. doi: 10.1158/1535-7163.MCT-12-0223. Epub 2012 Jun 4.

5.

Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.

Hsueh YS, Lin CL, Chiang NJ, Yen CC, Li CF, Shan YS, Ko CH, Shih NY, Wang LM, Chen TS, Chen LT.

PLoS One. 2013 Jun 20;8(6):e65762. doi: 10.1371/journal.pone.0065762. Print 2013.

6.

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.

Gastroenterology. 2005 Feb;128(2):270-9.

PMID:
15685537
7.

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.

Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

8.

Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.

Bosbach B, Deshpande S, Rossi F, Shieh JH, Sommer G, de Stanchina E, Veach DR, Scandura JM, Manova-Todorova K, Moore MA, Antonescu CR, Besmer P.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):E2276-83. doi: 10.1073/pnas.1115240109. Epub 2012 May 31.

9.

Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.

Guo T, Hajdu M, Agaram NP, Shinoda H, Veach D, Clarkson BD, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2009 Nov 15;15(22):6862-70. doi: 10.1158/1078-0432.CCR-09-1315. Epub 2009 Oct 27.

10.

Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.

Zhao J, Quan H, Xu Y, Kong X, Jin L, Lou L.

Cancer Sci. 2014 Jan;105(1):117-25. doi: 10.1111/cas.12320. Epub 2014 Jan 4.

11.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-5755. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.

12.

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.

Caenepeel S, Renshaw-Gegg L, Baher A, Bush TL, Baron W, Juan T, Manoukian R, Tasker AS, Polverino A, Hughes PE.

J Exp Clin Cancer Res. 2010 Jul 15;29:96. doi: 10.1186/1756-9966-29-96.

13.

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Todd JR, Becker TM, Kefford RF, Rizos H.

Pigment Cell Melanoma Res. 2013 Jul;26(4):518-26. doi: 10.1111/pcmr.12107. Epub 2013 May 13.

PMID:
23582185
14.

Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.

Liu NN, Ohkouchi M, Hashikura Y, Kajimoto N, Matsuda I, Isozaki K, Toh Y, Takahashi T, Nishida T, Hirota S.

Lab Invest. 2013 May;93(5):502-7. doi: 10.1038/labinvest.2013.43. Epub 2013 Mar 4.

15.

[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

Italiano A, Bui B.

Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Review. French.

16.

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B.

Ann Surg Oncol. 2012 May;19(5):1551-9. doi: 10.1245/s10434-011-2120-6. Epub 2011 Nov 8.

PMID:
22065192
17.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J.

Blood. 2006 Aug 15;108(4):1374-6. Epub 2006 Apr 27.

19.

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schöffski P, Marynen P, Debiec-Rychter M.

Clin Cancer Res. 2008 Sep 15;14(18):5749-58. doi: 10.1158/1078-0432.CCR-08-0533.

20.

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.

Gebreyohannes YK, Schöffski P, Van Looy T, Wellens J, Vreys L, Cornillie J, Vanleeuw U, Aftab DT, Debiec-Rychter M, Sciot R, Wozniak A.

Mol Cancer Ther. 2016 Dec;15(12):2845-2852. Epub 2016 Oct 24.

PMID:
27777285

Supplemental Content

Support Center